Neurocentrx

https://www.neurocentrx.com/

Background

Neurocentrx is a clinical-stage biopharmaceutical company developing the world’s first abuse-deterrent, immediate-release oral ketamine therapy designed for both in-clinic and at-home care settings. Headquartered in Edinburgh, Scotland, with global research collaborations and operations in Australia and the United States, our mission is to transform how care is delivered for people suffering from treatment-resistant mood disorders.